MALVERN, Pa., Oct. 19, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc.  (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced that its head of Research

MALVERN, Pa., Oct. 16, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc.  (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced the Compensation

MALVERN, Pa., Sept. 23, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc .  (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to fight COVID-19, today announced that its Chairman, CEO, and

MALVERN, Pa., Sept. 17, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc.  (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced the Compensation

MALVERN, Pa., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc .  (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to fight COVID-19, today announced that it will be participating in

(BPT) - By Shankar Musunuri, PhD, MBA, Chairman, CEO and Co-Founder, Ocugen After a summer of hope, the COVID-19 positivity rate has been spiking in the United States. Due in part to the highly transmissible and fast-spreading Delta variant, the number of cases of COVID-19 is up more than 107% vs.

MALVERN, Pa., Aug. 20, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc.  (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced the Compensation

         Conference Call and Webcast Today at 8:30 a.m. ET Rolling regulatory submission to Health Canada completed and review process initiated; U.S. FDA talks continue Multiple milestones achieved across regulatory and supply chain to support potential commercialization of pipeline assets The

MALVERN, Pa., July 30, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced that it will host a

MALVERN, Pa., July 16, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc.  (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced the Compensation